Last reviewed · How we verify
Helioblock SX
Helioblock SX is a Small molecule drug developed by Loreal USA. It is currently in Phase 3 development for UV protection and photoprotection.
Helioblock SX is a topical sunscreen agent that provides broad-spectrum UV protection by absorbing and reflecting ultraviolet radiation.
Helioblock SX is a small molecule intervention used in clinical trials to study its effects on dry skin and sunburn. It was tested in a completed study (NCT00368563) to determine its ability to moisturize skin.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Helioblock SX |
|---|---|
| Sponsor | Loreal USA |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
The product is designed to protect skin from harmful UV exposure, likely combining multiple UV filters to achieve broad-spectrum protection (UVA and UVB). As a cosmetic/dermatological product from L'Oréal, it functions as a photoprotective barrier rather than a systemically-acting pharmaceutical agent.
Approved indications
- UV protection and photoprotection
Common side effects
Key clinical trials
- Clinical Safety Trial of Long-Term Intermittent Use of Helioblock® SX Cream (PHASE3)
- A Capacitance and Transepidermal Water Loss Test to Determine the Ability of Sunscreen to Moisturize Skin (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Helioblock SX CI brief — competitive landscape report
- Helioblock SX updates RSS · CI watch RSS
- Loreal USA portfolio CI
Frequently asked questions about Helioblock SX
What is Helioblock SX?
How does Helioblock SX work?
What is Helioblock SX used for?
Who makes Helioblock SX?
What development phase is Helioblock SX in?
Related
- Manufacturer: Loreal USA — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for UV protection and photoprotection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing